The Phase II study (TACTI-002) in 1st line metastatic non-small cell lung carcinoma investigating
eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: updated results from a PD-L1
unselected population.
This is getting an oral presentation because of positive results.
Relatlimab got approval with a 25% increase in efficacy.
Earlier TACTI-002 results show eftilagimod doubled efficacy.
If updated results show this trend holds up we could see approval and sales within a year.
- Forums
- ASX - By Stock
- Ann: Immutep to announce new TACTI-002 data at ASCO 2022
The Phase II study (TACTI-002) in 1st line metastatic non-small...
-
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
34.5¢ |
Change
0.005(1.47%) |
Mkt cap ! $501.1M |
Open | High | Low | Value | Volume |
34.0¢ | 36.0¢ | 33.5¢ | $2.184M | 6.253M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 156342 | 34.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
35.0¢ | 107414 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 156342 | 0.345 |
8 | 173610 | 0.340 |
5 | 216592 | 0.335 |
11 | 170484 | 0.330 |
5 | 23066 | 0.325 |
Price($) | Vol. | No. |
---|---|---|
0.350 | 107414 | 4 |
0.355 | 87437 | 2 |
0.360 | 96232 | 4 |
0.365 | 117195 | 6 |
0.370 | 119996 | 5 |
Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |